Complejo Asistencial Universitario de León

Futó vizsgálatok

• Toboroz

  Heart Failure in Women: Epidemiological and Prognostic Insights

  NCT07847983· Carolina Ortiz Cortes· Forrás

• Toboroz

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Forrás

• Fut, nem toboroz

  Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

  NCT06282978· 2. fázis· PETHEMA Foundation· Forrás

• Toboroz

  NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

  NCT05558319· 3. fázis· PETHEMA Foundation· Forrás

• Toboroz

  Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

  NCT05673681· Fundación Academia Española de Dermatología· Forrás

• Fut, nem toboroz

  Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

  NCT03742297· 3. fázis· PETHEMA Foundation· Forrás

• Toboroz

  Thoracic Tumours Register

  NCT02941458· Spanish Lung Cancer Group· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok2 toboroz
• Melanóma1 toboroz
• Mielóma multiplex1 toboroz
• Pitvarfibrilláció1 toboroz
• Stroke (szélütés)1 toboroz
• Szívelégtelenség1 toboroz

Lezárt vizsgálatok

• Toboroz

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Forrás

• Lezárult

  Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· 2. fázis· BeiGene· Forrás

• Lezárult

  ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

  NCT04603183· 2. fázis· MedSIR· Forrás

• Lezárult

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Forrás

• Lezárult

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· 3. fázis· Takeda· Forrás

• Lezárult

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· 3. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

  NCT02448420· 2. fázis· SOLTI Breast Cancer Research Group· Forrás